Prot #Ad-p53-002: A Phase 2, Multi-Center, Open Label Study to Evaluate Efficacy and Safety of Adenoviral p53 (Ad-p53) in Combination with Immune Checkpoint Inhibitor Therapy in Patients with Progression or Recurrence of Head and Neck Squamous Cell Carcin